In a story that is being mostly censored in the U.S. media, vaccine manufacturer Sanofi Pasteur has admitted that their vaccine for dengue (a deadly tropical disease spread mostly by mosquitoes) is defective.
In a press release from France, the pharmaceutical company admitted that the vaccine is harmful to those not previously infected with dengue, and could cause children not previously infected with dengue to contract a severe case of the disease.
Their press release states:
Based on up to six years of clinical data, the new analysis evaluated long-term safety and efficacy of Dengvaxia in people who had been infected with dengue prior to vaccination and those who had not.
The analysis confirmed that Dengvaxia provides persistent protective benefit against dengue fever in those who had prior infection.
For those not previously infected by dengue virus, however, the analysis found that in the longer term, more cases of severe disease could occur following vaccination upon a subsequent dengue infection.